Asudemotide

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30058598 | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019678 | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015815

Asudemotide, also known as S-588410, an immunostimulant that was studied as adjuvant therapy in phase III clinical trials for patients with esophageal cancer. In addition, this drug participated in phase II clinical trials after first-line chemotherapy in patients with advanced and/or metastatic bladder cancer.

Originator

Approval Year

PubMed

Title	Date	PubMed
Immunotherapy for esophageal squamous cell carcinoma: a review.	2018-08-29	30058598

Sample Use Guides

In Vivo Use Guide

S-588410 (Asudemotide) will be injected subcutaneously once weekly for 12 weeks and once every 2 weeks thereafter for 94 weeks.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Wed Apr 02 19:43:19 GMT 2025` Edited by `admin` on `Wed Apr 02 19:43:19 GMT 2025`
Protein Type	PEPTIDE
Protein Sub Type	T-CELL ANTIGEN
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	30Q33TZ6A7
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

Cancer Peptide Vaccine S-588410 component S-288301

Preferred Name

English

Asudemotide

Official Name

English

Cancer Peptide Vaccine S-588410 component asudemotide

Code

English

L-ISOLEUCINE, L-.ALPHA.-GLUTAMYL-L-TYROSYL-L-TYROSYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-PHENYLALANYL-L-VALYL-L-ASPARAGINYL-

Systematic Name

English

HUMAN DEP DOMAIN-CONTAINING PROTEIN 1A-(294-302)-PEPTIDE

Common Name

English

S-588410 component asudemotide

Code

English

asudemotide [INN]

Common Name

English

GLU-TYR-TYR-GLU-LEU-PHE-VAL-ASN-ILE

Systematic Name

English

S-288301

Code

English

Code System Code Type Description

NCI_THESAURUS

C121776